Novartis AG ADR (NVS)vsUFP Technologies Inc (UFPT)
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
UFPT
UFP Technologies Inc
$277.89
+0.18%
HEALTHCARE · Cap: $2.16B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 8876% more annual revenue ($56.69B vs $631.64M). NVS leads profitability with a 22.5% profit margin vs 11.5%. NVS appears more attractively valued with a PEG of 3.22. UFPT earns a higher WallStSmart Score of 60/100 (C+).
NVS
Buy51
out of 100
Grade: C-
UFPT
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Intrinsic value data unavailable for UFPT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
15.1% revenue growth
Earnings expanding 21.3% YoY
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Premium valuation, high expectations priced in
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : UFPT
The strongest argument for UFPT centers on Altman Z-Score, Debt/Equity, Revenue Growth. Revenue growth of 15.1% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : UFPT
The primary concerns for UFPT are P/E Ratio, PEG Ratio.
Key Dynamics to Monitor
NVS profiles as a value stock while UFPT is a growth play — different risk/reward profiles.
UFPT carries more volatility with a beta of 1.07 — expect wider price swings.
UFPT is growing revenue faster at 15.1% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
UFPT scores higher overall (60/100 vs 51/100) and 15.1% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →UFP Technologies Inc
HEALTHCARE · MEDICAL DEVICES · USA
UFP Technologies, Inc. designs and converts foams, films and plastic materials for the medical, automotive, consumer, electronic, industrial, aerospace and defense markets in the United States. The company is headquartered in Newburyport, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?